Denmark confirms excessive-pricing decision
Denmark’s Competition Appeals Tribunal has confirmed findings by the country’s antitrust authority that drug distributor CD Pharma abused its dominant position in the market for the distribution of a stimulant drug by raising its price by 2000%.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.